JP2021529805A5 - - Google Patents

Info

Publication number
JP2021529805A5
JP2021529805A5 JP2021500178A JP2021500178A JP2021529805A5 JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5 JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021500178 A JP2021500178 A JP 2021500178A JP 2021529805 A5 JP2021529805 A5 JP 2021529805A5
Authority
JP
Japan
Prior art keywords
ivosidenib
powder
ray diffraction
diffraction pattern
dsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021500178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529805A (ja
JP7621242B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/040257 external-priority patent/WO2020010058A1/en
Publication of JP2021529805A publication Critical patent/JP2021529805A/ja
Publication of JP2021529805A5 publication Critical patent/JP2021529805A5/ja
Priority to JP2024131926A priority Critical patent/JP2024150784A/ja
Application granted granted Critical
Publication of JP7621242B2 publication Critical patent/JP7621242B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500178A 2018-07-06 2019-07-02 イボシデニブ形態および医薬組成物 Active JP7621242B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024131926A JP2024150784A (ja) 2018-07-06 2024-08-08 イボシデニブ形態および医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862694596P 2018-07-06 2018-07-06
US62/694,596 2018-07-06
PCT/US2019/040257 WO2020010058A1 (en) 2018-07-06 2019-07-02 Ivosidenib forms and pharmaceutical compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024131926A Division JP2024150784A (ja) 2018-07-06 2024-08-08 イボシデニブ形態および医薬組成物

Publications (3)

Publication Number Publication Date
JP2021529805A JP2021529805A (ja) 2021-11-04
JP2021529805A5 true JP2021529805A5 (enExample) 2022-07-12
JP7621242B2 JP7621242B2 (ja) 2025-01-24

Family

ID=69059942

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021500178A Active JP7621242B2 (ja) 2018-07-06 2019-07-02 イボシデニブ形態および医薬組成物
JP2024131926A Withdrawn JP2024150784A (ja) 2018-07-06 2024-08-08 イボシデニブ形態および医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024131926A Withdrawn JP2024150784A (ja) 2018-07-06 2024-08-08 イボシデニブ形態および医薬組成物

Country Status (18)

Country Link
US (1) US12264148B2 (enExample)
EP (2) EP4603147A3 (enExample)
JP (2) JP7621242B2 (enExample)
KR (2) KR20250164882A (enExample)
CN (1) CN112367995A (enExample)
AU (2) AU2019299352B2 (enExample)
BR (1) BR112021000156A2 (enExample)
CA (1) CA3103498A1 (enExample)
EA (1) EA202190217A1 (enExample)
IL (3) IL327008A (enExample)
MA (1) MA53099A (enExample)
MX (2) MX2021000068A (enExample)
PH (1) PH12021550017A1 (enExample)
SG (1) SG11202012763TA (enExample)
TW (2) TWI911130B (enExample)
UA (1) UA129800C2 (enExample)
WO (1) WO2020010058A1 (enExample)
ZA (1) ZA202008034B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4010331T (pt) * 2019-08-08 2024-01-08 Servier Lab Um método de preparação do ivosidenib e de um seu intermediário
GB201912411D0 (en) * 2019-08-29 2019-10-16 Johnson Matthey Plc Crystalline forms of ivosidenib
AR133410A1 (es) 2023-08-01 2025-09-24 Servier Lab Cocristal de un inhibidor de idh1, proceso de preparación del mismo, composiciones farmacéuticas del mismo, y métodos de tratamiento que implican el mismo

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
CN103459394B (zh) * 2011-04-08 2016-04-27 辉瑞大药厂 结晶和非结晶形式的托法替尼,以及包含托法替尼和渗透增强剂的药物组合物
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
JO3479B1 (ar) * 2012-09-06 2020-07-05 Bayer Healthcare Llc تركيبة دوائية مغلفة تحتوي على ريجورافنيب
PH12021551647A1 (en) * 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
SMT202100444T1 (it) * 2014-03-14 2021-09-14 Les Laboratories Servier Sas Composizioni farmaceutiche di composti terapeuticamente attivi
MD3362066T2 (ro) * 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
CA3015753A1 (en) 2016-02-26 2017-08-31 Celgene Corporation Idh2 inhibitors for the treatment of haematological maligancies and solid tumours
EP3717470A1 (en) * 2017-11-27 2020-10-07 Assia Chemical Industries Ltd Solid state forms of ivosidenib

Similar Documents

Publication Publication Date Title
TWI788702B (zh) {[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
JP5546717B2 (ja) アリピプラゾール結晶質形態を調製する方法
JP6634368B2 (ja) 複素環式化合物及びそれらの使用
JP2022532404A (ja) N-[4-(クロロジフルオロメトキシ)フェニル]-6-[(3r)-3-ヒドロキシピロリジン-1-イル]-5-(1h-ピラゾール-5-イル)ピリジン-3-カルボキサミドの結晶性形態
US12365680B2 (en) Polymorphs of the hydrochloride salt of linaprazan glurate
WO2004000317A1 (en) Pharmaceutical composition containing stabilised amorphous form of donepezil hydrochloride
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
WO2016125190A2 (en) Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
JP5782438B2 (ja) アミド化合物の結晶
FR2883285A1 (fr) Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl) -1,2,3,6-tetrahudro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique
US20130225830A1 (en) Polymorphs of febuxostat
TW201311240A (zh) 非晶形哌啶基化合物之生物可利用組合物
JP2026503095A (ja) リナプラザングルレート(linaprazan glurate)の臭化水素酸塩の多形
JP2013501751A (ja) 経口用固体製剤および結晶形態のアポトーシスタンパク質インヒビター
JP2024542115A (ja) リナプラザングルレートのメシラート塩の多形体
JP5530369B2 (ja) 新規な結晶形
JP2007269628A (ja) 医薬化合物の結晶
JP6393310B2 (ja) 5−クロロ−チオフェン−2−カルボン酸[(s)−2−[メチル−3−(2−オキソ−ピロリジン−1−イル)−ベンゼンスルホニルアミノ]−3−(4−メチル−ピペラジン−1−イル)−3−オキソ−プロプリル]アミドの酒石酸塩
JP2019530719A (ja) 4−(2−((1r,2r)−2−ヒドロキシシクロヘキシルアミノ)ベンゾチアゾール−6−イルオキシ)−n−メチルピコリンアミドの結晶形
KR101423630B1 (ko) 비칼루타미드와 니코틴아미드의 공결정
JP2026503096A (ja) リナプラザングルレート(linaprazan glurate)のマレイン酸塩の多形
HK40092799A (en) Polymorphs of a hydrochloride salt of pn6047
JP2023115525A (ja) ロスバスタチンアリルエステルの結晶形態
JP2004168772A (ja) 受容体調節剤
CA3079142A1 (en) Amorphous form of pimavanserin hemitartrate